Aerosol drug delivery: developments in device design and clinical use/Authors' reply

[...] they state that a flow rate of 60 L/min might be difficult to achieve for patients with severe chronic obstructive pulmonary disease (COPD). The distribution of the drug within the central, intermediate, and peripheral regions of the lung, however, remained unchanged.1 Additionally, the time a...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2011-09, Vol.378 (9795), p.981
Main Authors: Rottier, Bart, Grasmeijer, Floris, Hagedoorn, Paul, de Boer, Anne Haaije, Smith, James, Tiner, Richard, Dolovich, Myrna, Dhand, Rajiv
Format: Article
Language:English
Subjects:
Carbon dioxide
Design
Emissions
Greenhouse gases
Health services
Respiratory therapy
Sustainable development
Technological change
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...] they state that a flow rate of 60 L/min might be difficult to achieve for patients with severe chronic obstructive pulmonary disease (COPD). The distribution of the drug within the central, intermediate, and peripheral regions of the lung, however, remained unchanged.1 Additionally, the time at which peak IFR is achieved during the inhalation is important and differs between drypowder inhalers (DPIs) that dispense powder from a capsule versus those that use a drug reservoir.2 The Diskus DPI provides a consistent emitted dose at the mouth over an IFR range of 15-60 L/min.3 However, the fine particle fraction increases as the IFR through the device increases from 30 to 60 L/min.4 The ability of the aerosol to bypass the upper airway and deposit in the lung is dependent on both the IFR and the size distribution of the inhaled aerosol. [...] to other DPIs, a greater proportion of the dose of drug generated with the Diskus at lower IFRs is likely to deposit in the upper airway, with less available for the lung.1 Further studies are needed to elucidate the pulmonary deposition and therapeutic responses at various IFRs.
ISSN:0140-6736
1474-547X